J&J’s bispecific combo slashes myeloma progression risk by 89% in phase 3 trial

Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple myeloma, delivering another catalyst that could add a new twist in the | Johnson & Johnson has unveiled remarkable phase 3 survival data for its dual bispecific combination in earlier-line multiple myeloma, potentially adding a new twist in the commercial trajectories of off-the-shelf T-cell engagers versus personalized CAR-T therapies.